TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05233384

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: For each patient included, this study will involve the collection of 20 ml of blood during a blood test carried out as part of routine care. One EDTA tube (4,5 ml) will be withdrawn and frozen for genetic testing. 15 ml of citrated blood sample (3 to 5 tubes, depending on the used tubes) are necessary for the study of fibrin clot structure. Citrated tubes will be double centrifugated and frozen (-80°C) according to Groupe Français d'Études sur l'Hémostase et la thrombose guidelines (centrifugation protocol: 1500 to 2000g at least 15min, or 2000 to 2500g at least 10min with an intermediate decantation).
Study: NCT06009809

Intervention type: DIAGNOSTIC_TEST
Intervention: transesophageal echocardiogram
Description: To measure mean blood velocity at the level of the right renal and superior mesenteric artery
Study: NCT05908500

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR Training
Description: Various methods of CPR training are implemented and compared

Intervention type: OTHER
Group type: OTHER
Intervention: CPR Training
Description: Various methods of CPR training are implemented and compared
Study: NCT00000774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rgp120/HIV-1MN
Description: Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rgp120/HIV-1 SF-2
Description: Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo version of rgp120/HIV-1MN
Description: Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo version of rgp120/HIV-1SF2
Description: Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
Study: NCT06020209

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Computed Tomography
Description: A comprehensive CCT protocol will be performed in the post-acute phase of STEMI. Specifically, the CCT protocol will include a pre-contrast scan and an angiographic scan ( also set up to assess ventricular volume and function) followed by late contrast enhancement scan.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance
Description: A comprehensive CMR protocol will be performed in the post-acute phase of STEMI. Specifically, the CMR protocol is designed for morpho-functional analysis and tissue characterisation (including assessment of late gadolinium enhancement and mapping). CMR will be considered the gold standard.
Study: NCT06330220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: intravitreal injection
Study: NCT04902729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Patient is given carbetocin (80mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patient is given oxytocin (1IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
Study: NCT04748172

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 virus vaccines
Description: mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna)

Intervention type: DIAGNOSTIC_TEST
Intervention: AMH sampling
Description: Blood sample for AMH on recruitment and after three months

Intervention type: DIAGNOSTIC_TEST
Intervention: anti Covid-19 antibody levels (Serology)
Description: Blood sample for IgG against S1 protein after three months
Study: NCT05615233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TACAD
Description: Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of PLAD (TACAD). It includes four components in three languages (English, MandarinChinese, and Korean):~1. 2 sub-ethnic specific social media sites;~2. interactive online educational modules;~3. online resources; and~4. a VR component based on A Walk Through Dementia (WTD)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alzheimer's Association website
Description: The webpage on caregiving includes information on caregiving, care option, financial/legal planning, caregiver health, daily care, stages and behaviors, and safety. The content will be available in the three languages at the project website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alzheimer's Association website
Description: The webpage on caregiving includes information on caregiving, care option, financial/legal planning, caregiver health, daily care, stages and behaviors, and safety. The content will be available in the three languages at the project website.
Study: NCT06325670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BED treatment
Description: A 12 session cognitive behavioural intervention in groups for Danish adults with type 2 diabetes and Binge Eating Disorder.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist
Description: A waitlist control group that receives regular type 2 diabetes treatment while waiting to receive the BED treatment intervention.
Study: NCT05011097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y150
Description: Subjects will receive an intravenous infusion of Y150 in a dose escalation once a week for a 28-day treatment cycle until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Study: NCT04930614

Intervention type: OTHER
Intervention: Survey on socio-demographic variables and healthcare-seeking, sexual and drug-using behaviour
Description: Digital survey to estimate the associated risk factors for HIV infections in transgender and non-binary people in Flanders and Brussels (Belgium)
Study: NCT06050018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YesMilkdiet
Description: In the YesMilkdiet the participants will consume Milk and dairy products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NoMilkdiet
Description: In the NoMilkdiet the participants will not consume milk or dairy products only another sources of proteins
Study: NCT05845840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-297
Description: Escalating doses of BRII-297 will be given in different cohorts i.e., Cohorts 1 through 6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating doses of placebo will be given in different cohorts i.e., Cohorts 1 through 6
Study: NCT05140616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: After screening according to inclusion and exclusion criteria, patients meeting the criteria were enrolled. Treatment regimen: Chidamide 15mg biw po, lasted for 8 weeks. Pretransplant use of Chidamide for reasons other than cGVHD, such as for the treatment of leukemia or lymphoma, was permitted.All patients received systemic corticosteroid therapy for cGVHD prior to and during the study; concomitant use of other immunosuppressive therapies was also permitted, however, pre-existing corticosteroid and immunosuppressant doses must have been stable for 14 days before initiating Chidamide. Doses of concomitant corticosteroids and immunosuppressants could be tapered during the study as clinically indicated.
Study: NCT05942924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeated tactile stimulation
Description: See arm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective tactile stimulation
Description: See arm
Study: NCT04760379

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration therapy
Description: Focal muscle vibrator (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
Study: NCT05679180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micropulse laser
Description: treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
Study: NCT06271564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnetite ZnO Composite Nanoparticles
Description: Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo Gel
Description: Topical placebo gel containing water, glycerin and Hydroxypropyl methylcellulose will be applied 3 times daily for 6 weeks as a positive control group
Study: NCT04719468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance with ballet elements
Description: Ballet-based dance sessions will be delivered by trained artists within the English National Ballet group in a professional dance space/ delivered remotely, COVID-19 permitting.
Study: NCT04810559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test
Description: OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test in oral fluid and fingerstick blood conducted by untrained healthcare providers compared to laboratory 4th generation Ag/Ab EIA results performed on venous blood.
Study: NCT04699123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318 800 mg
Description: NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318 800 mg
Description: NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318 800 mg
Description: NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318 400 mg
Description: NC318 will be given intravenously (IV) every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC318 400 mg
Description: NC318 will be given intravenously (IV) every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be given IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be given IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be given IV every 3 weeks
Study: NCT04811118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel for Injection (Albumin-bound)
Description: Docetaxel for Injection (Albumin-bound) by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere
Study: NCT04959461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: webCHAT
Description: A self-guided, single session web intervention that utilizes a motivational interviewing style to prevent impaired driving

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: 6 hours of driver education
Study: NCT05730517

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CP5HA
Description: Test group 1 will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL); continuous administration of investigational product for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo syrup
Description: Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CP5
Description: Test group 2 will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 16 weeks.
Study: NCT05068271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Domain Exercise Program
Description: The multi-domain exercise consisted of the main exercise (e.g., aerobic exercise, resistance exercise, flexibility training, and coordinative exercise), social interaction, and meditation. Participants are encouraged to engage in 150 min exercise per week consisting of one 90-min on-site session and multiple online sessions for 6 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group
Description: The usual physical activity group, as the control group, is informed to maintain their lifestyles. In addition, participants are invited to attend one 60-min online educational course per week. The logs of physical activity behavior will be obtained from the participants once per month during the intervention period.
Study: NCT06236828

Intervention type: DEVICE
Intervention: Mechanical Thrombectomy
Description: The endovascular mechanical thrombectomy methods mainly include stent retriever thrombectomy, ADAPT thrombus aspiration technique, or their combination.
Study: NCT05729581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The educational programme on sustainable and healthy diet and breastfeeding
Description: In the interventional group the educational programme of sustainable diet and breastfeeding will be provided before the delivery to see the impact on the prevalence of the breastfeeding at 1 and 6 months after delivery (compared with the group of control, without intervention)
Study: NCT06083701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib in combined with Chidamide
Description: * Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;~* Phase 2: dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;
Study: NCT05310526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Group
Description: Training for prescribing the Brazilian cardioprotective diet
Study: NCT05436678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrimeC 748 mg
Description: PrimeC is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 750 MG
Description: Ciprofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Celecoxib
Study: NCT05710679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: The intervention consist in a blood sample that will be taken twice :~* at the inclusion (before treatment)~* 3 months after the potentiated radiotherapy in case of incomplete response (PET-CT)
Study: NCT05584800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZGGS18 for Injection
Description: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kgof ZGGS18，intravenous infusion, once every 2 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZGGS18 for Injection
Description: Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18，intravenous infusion, once every 2 weeks.
Study: NCT05595408

Intervention type: DRUG
Intervention: Adjuvant chemotherapy
Description: cisplatin/carboplatin-gemcitabine 4-6 cycles

Intervention type: DRUG
Intervention: adjuvant immunotherapy
Description: immunotherapy for one year
Study: NCT05677230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon occluded/plug assisted retrograde transvenous obliteration.
Description: Balloon occluded/plug assisted retrograde transvenous obliteration will be done one time only.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Obturation
Description: Endoscopic Variceal Glue Therapy will be done till obturation every 3 weekly.
Study: NCT05753501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-101
Description: Oral:Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-101
Description: Oral:Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-101
Description: Oral:Tablet
Study: NCT05330468

Intervention type: DEVICE
Intervention: Abbott Mechanical Heart Valve (MHV) Regent™
Description: SJM Regent™- Standard cuff (Model number AGN-751); SJM Regent™- FlexCuff™ (Model number AGFN-756)
Study: NCT05676476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Description: Antihypertensive treatment to goal of less than 140/90 mmHg
Study: NCT05538091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
Study: NCT06338618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver treatment protocol
Description: The liver treatment protocol consists of performing twelve visceral manual techniques in an approximate time of 30 minutes twice a week for 4 weeks
Study: NCT05844163

Intervention type: OTHER
Intervention: observation
Description: observation

Intervention type: OTHER
Intervention: observation
Description: observation
Study: NCT06344806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified Breastfeeding Education
Description: Breastfeeding education content will be integrated into the game program designed with the gamification technique. A training program will be applied to the women in the experimental group in the last trimester. Women in the control group will receive the standard breastfeeding training in the hospital. Measurement tools will be applied to all participants before and after the training.
Study: NCT05844163

Intervention type: OTHER
Intervention: observation
Description: observation
Study: NCT04778787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
Description: Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
Description: Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy
Study: NCT05693545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenoxymethyl penicillin
Description: Prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intramuscular benzathine penicillin G (BPG) prophylaxis
Description: Prophylaxis
Study: NCT05762055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titan nanoLOCK interbody cage
Description: Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACDF interbody cage
Description: Anterior cervical discectomy and fusion (ACDF) is an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology
Study: NCT05523479

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preventive post-extubation high-flow nasal cannula oxygen (HFNC)
Description: Preventive post-extubation HFNC for all eligible patients (without risk stratification)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preventive post-extubation high-flow nasal cannula oxygen (HFNC)
Description: Preventive post-extubation HFNC for all eligible patients (without risk stratification)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preventive post-extubation high-flow nasal cannula oxygen (HFNC)
Description: Preventive post-extubation HFNC for all eligible patients (without risk stratification)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preventive post-extubation high-flow nasal cannula oxygen (HFNC)
Description: Preventive post-extubation HFNC for all eligible patients (without risk stratification)
Study: NCT04984278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Description: oromucosal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oromucosal spray
Study: NCT06433505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BMS-986365
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BMS-986409 + BMS-986410
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BMS-986410 + BMS-986409
Description: Specified dose on specified days
Study: NCT06109376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypothermia
Description: In this trial, intra-arterial select cooling infusion is used to reduce brain tissue temperature to 33-35°C.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy
Description: Thrombectomy includes treatment with stent retrievers and/or thromboaspiration, balloon angioplasty, stenting, intra-arterial thrombolysis, or the various combinations of these approaches.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thrombectomy
Description: Thrombectomy includes treatment with stent retrievers and/or thromboaspiration, balloon angioplasty, stenting, intra-arterial thrombolysis, or the various combinations of these approaches.